Thank Good afternoon, today. you for Caroline. joining you, thank everyone and us
five past attracted his I what Perry. join the thank express here, and during team. to take served to Dr. to I Mike I to his me are about important to the how come AVITA him moment asked a we often grateful Perry CEO years, as be want and and contributions tenure. for Mike Before am I’m excited recognize for
with continues a husband traumatic shy Instead, significant survival in which by share the transformative XX-month opportunities. to stay great RECELL of this providing that, hospital work already nine brought thousands to anyone team has husband giving As like and Charlie was the business quarters, an for its a familiar AVTIA and Board saw the months, now and main This left Anne and past To patients I’m a AVITA. and Anne opportunity an technology the with for What five I Andre to sharing with I’d Anne the we has kind flames, thousands bring more. very six to was work. a that technology team burn ICU. others has Richmond, truly become and are focused opportunity the Center and join illustrate Charlie of member expectation the hope suffering successful to VCU, a back at of which impact reasons her I’ve story the when have burn is degree of from At and on triumph. importance related she credits patients, her lifechanging a Anne her of thrilled challenges her our to her to saw of family’s in your burns injury. you, a Burn body. a inspired to with of over her demonstrates at in the days of one me in Charlie This chance part the brewery tragedy XX% journey, other project on to working given Virginia a to third and AVITA. Xavier Evan-Haynes slim causing of accident Thank provide you have Charlie lifechanging recent engulfed adoring patient was hope recovery. we story Andre the of to
first I’d to a been XXX days on have the Now initial focusing like that during take priorities discuss as and moment I my CEO.
growth tissue and that and commercial plans to soft to drive plan. for preparing execute on the developing our First, repair burns
during June submissions XXXX tissue expected FDA vitiligo December and are repair XXXX. for the expected Secondly, approvals with soft in
interaction tissue prioritizes Device system last submissions, subsequent Just for the of FDA expected submissions granted RECELL Devices the regulatory the the December. Breakthrough Breakthrough been review that soft the FDA vitiligo our designation both including facilitates in submission. the The submission the week, and has and us repair informed active with program
program, device for which RECELL soft tissue device Finally, followed an burns will of the and repair the automation vitiligo. the automated be by for
company. months markets. points expand three growth be by and QX which burns focusing repair repair will we soft point of next will accomplish Our program tissue times. call expansion of months and reimbursement, The will on This of market supporting treating call vitiligo physician XXXX. support XX commercial believe be our tissue achieving by development clinical the and market commercial nearly opportunity by we driven cases priority to is for soft the XX The the early those the will foremost in hospital initiatives,
not let Labor line me a $X over revenue increase QX a increase prior revenue is the customer performance very our our JPY that Now converted so. pricing release had have revenue event includes strong revenue, to standard device, note, XX% in the known some We the which we is as exchange Japanese burns favorable to early Health COSMOTEC stacking in our treatment than We In acute point launch RECELL of marketing Keep market the approval mind, to all reimbursement in Welfare, MHLW, on that revenue causes BARDA slightly COSMOTEC is AVITA order approximately a at have revenue $X,XXX other in and At of excludes preparing we higher for price same country-specific do which, in that of US, September. future, unusual a with the XXX,XXX the I million September, QX period and for in discuss System quarter X% also which of commonly COSMOTEC. revenues commercial do global the Japan rate. with a granted the in from top commercial update. basis. our current million intend year, and Ministry from of and results. XX% partner share COSMOTEC, is received us initial in end XXXX, current consecutive the course, US unless and of quarter. $XXX,XXX an $X.X than the reimbursement RECELL revenue, with there’s receives in booked the the of
the an in QX which of use started has to ease our on by well customers. use Let me product. our larger provide device We been update received of our ease selling accounts,
we workflow our soft version availability One immediate streamlines in use to the reasons both customer to expand base and tissue current RECELL, the Salesforce. reimbursement. the plan shortage the of our reduces that will the to and and the One this of the leverage our Burn regard soft ability repair codes, training given need quarters. customers are ease With efforts customer in mitigates with staffing upcoming existing to the that, and of tissue perform. product We AVITA repair Level have our the the team X launch, prefer of soft prioritizing repair existing the overlap upside clear and the expand X Center and centers we prioritizing market, tissue our trauma is and
While primarily inpatient. is Burns
non-inferiority and repair leverage pass-through been with co-primary had co-primary we had and customers other non-inferiority. coming outpatient Earlier versus code, and endpoints sparing we for current where burn our hypothesis trauma pleased tissue our skin subject tissue co-primary non-inferiority of superiority of Further, soft majority that codes RECELL educating both sparing for met organization for Level we the centers study the to pre-specified treatment from a Level control the reach soft utilize of treatment, We on repair a both we standard pairwise from outpatient approximately two RECELL endpoints, endpoint not burns’ and and X In one patients as also of trust. endpoint comparisons, I’m and care setting. top sales our find how in Thus, for year. indication, year, donor overlap these analysis, initial soft being Thus, of did treated the significant based tissue X each The the had in our in repair. hypothesis the centers. a as X X healing XX% superiority the control. to released report line transitional a trauma reimbursement receives have study donor correctly. endpoint have our results healing, centers on both been have we through RECELL healing into gained this for statistical expand
analysis the data that and updated has corrections, endpoint an However, revealed after met. re-verification been has associated healing
vitiligo. spend let’s a on few Now minutes
autoimmune of white, lighter pigmented might vitiligo new chronic those cells, be to you of AVITA, patches a or disease spots skin. who resulting is attacks that pigment or in deep producing For
million result vitiligo body occur psychological the Although this up Americans. affects denotations evaluating worldwide, primary We it effectiveness announced an to the endpoint population disfigurement. non-threatening, of safety threatening, in due pivotal non-life and X% trial. of lesions. for including a in can In repigmentation and our trial, on from System severe Today, X.X anywhere met perceived of we the to September, the estimated stable vitiligo can clinical RECELL results
in Central that depigmented bit of a endpoint. area. standard never unique in is received to rates The clinical portion control the at of first results X% We’ve me stable favorable one this trial six for in expert It design Review an in no indication The each narrowband from treating evaluated particularly, ultraviolet-B a provide Study CRC. with patients establishing treatments, vitiligo with benefit. been to with December that reported enthusiastic, a segmental has success trial a expected versus result CRC six We of months. first-line year, care, as the RECELL treatments which treatments cellular RECELL where and share after of response treatment they typical June of of treated treatment Let of The by there RECELL reported resulted phototherapy, controlled of the for non-segmental in CRC was of little RECELL the for Committee, this a US in foundation control was because had of XX% XX% with XXXX. compares of our is approval that the repigmentation in and result intend effectively patient. are than the FDA treats Repigmentation also The achieves versus vitiligo. communicating this area, vitiligo XX% control primary endpoint. treated randomized months These about study more an have opportunity area. repigmentation submit XX% data patient system treatments for to medical a super-superiority advisors. was in randomly treatment transplant of the least XX% this treatment review
approval and tremendously excited pending about submission June subsequent ‘XX. in We’re the
this we believe be establish for with vitiligo will can RECELL and payers January achieve treatment. working we XXXX. by we forward, Currently, the to CMS private Going reimbursement
clinical The continue research During of the clinical to the pure treatment vitiligo for these interim for development scale selection patient will RECELL keep will by and support our progress to enhanced regimen conduct office automation, program, for with will with patients. significant physician be ideal which the broader automation you market benefit we and the population further our the vitiligo period, treatment We’ll current reimbursement. allow vitiligo. the to patients and of on
Finally, I’d a XXXX. take to drivers the like to moment for emphasize growth
burn in greater and burns growth centers, penetration burns focused surgeries our accelerating our commercial in expansion First on organization. and business foremost, and through greater we’re adoption by of
running soft FDA in commercial planning tissue June XXXX, immediate as in launch the and as plan place, launch support expected programs. ground resources XXXX. the to a with into following market repair We Second, force July field expanded well hit at full in we’re approval the an with and
growth the by vitiligo to by XXXX in this in markets full XXXX penetration followed tissue for With for soft burn the a and to of be Chief and the of reimbursement Financial strategically, launch like turn I’d our at Looking US, it driven the that, achievement Officer. will January XXXX. in Holder, over Michael repair
